Biologic Therapies Summit XI Webcast Series
Emerging Treatments in iMIDS
Release date: July 10, 2025
Expiration date: July 9, 2027
Estimated Time of Completion: 2 hours and 45 minutes
Session Agenda
Signal and the Noise: Safety in Rheumatology
Michael Putman, MD, MSci
PsA
Christopher Ritchlin, MD, MPH
Difficult to Treat RA (D2TRA)
Jack Cush, MD
Emerging treatments on Lupus nephritis
Michelle Petri, MD, MPH
Advances in the treatment of inflammatory myopathies
Rohit Aggarwal, MD, MS
Description
Biologic Therapies Summit XI Webcast Series, repurposed from the 2025 Biologic Therapies Summit XI, is designed for healthcare professionals seeking to deepen their understanding of cutting-edge treatments for immune-mediated inflammatory diseases.
Faculty Disclosure
In accordance with the Standards for Integrity and Independence issued by the Accreditation Council for Continuing Medical Education (ACCME), Cleveland Clinic Center for Continuing Education mitigates all relevant conflicts of interest to ensure CME activities are free of commercial bias.
The following faculty have indicated they have no relationship which, in the context of his/her presentation(s), could be perceived as a potential conflict of interest
Rohit Aggarwal, MD | |
CSL Behring Astrazeneca Pharmaceuticals Alexion Kezar Life Sciences, Inc. Octapharma Kyverna ArgenX ANI Pharmaceuticals Artasome Cabaletta Bio Capella Bioscience Capstan Therapeutics, Inc. Corbus Galapagos Horizon Therapeutics I-Cell Immunovant Lilly Manta Medicines Corporation Novartis Nuvig Therapeutics NKarta Teva Tourmaline Bio Verismo Therapeutics |
Consulting |
Boehringer Ingelheim EMD Serono, Inc. Janssen Bristol-Myers Squibb Co. Pfizer PRoivant |
Consulting Research |
Abbvie Pharmaceuticals | Consulting (Ended: 01/01/2024) |
Jubilant DraxImage, Inc. | |
Roivant Sciences Ltd. | Consulting (Ended: 12/01/2024) |
Orbus Pharmaceuticals | Consulting (Ended: 12/01/2023) |
Cassandra Calabrese, DO | |
Astra Zeneca Sanofi-Regeneron |
Consulting Teaching and Speaking |
Lilly | Consulting (Ended: 12/01/2023) |
Pfizer | Consulting (Ended: 07/01/2023) |
Leonard Calabrese, DO | |
Astra Zeneca | Teaching and Speaking |
Sanofi Aventis | Consulting |
Genentech/Roche | Consulting Advisor or review panel participant Teaching and Speaking |
Novartis | Consulting |
UCB Janssen |
Consulting Teaching and Speaking |
Abbvie Pharmaceuticals | Consulting |
J. Jack Cush, MD | |
Bristol-Myers Squibb Co. Novartis UCB Abbvie Pharmaceuticals Sanofi |
Consulting Advisor or review panel participant |
M. Elaine Husni, MD | |
Lilly Amgen Bristol-Myers Squibb Co. Janssen AbbVie Pharmaceuticals |
Consulting Advisor or review panel participant |
Novartis Pharmaceuticals | Consulting Advisor or review panel participant Teaching and Speaking |
Pfizer, Inc. | Advisor or review panel participant |
UCB, Inc. | Consulting |
Regeneron | Consulting (Ended: 01/01/2024) Advisor or review panel participant (Ended: 01/01/2024) |
National Psoriasis Foundation | Other activities from which remuneration is received or expected Research |
Elizabeth Kirchner, DNP | |
Lilly | Consulting (Ended: 06/29/2023) |
Pfizer | Consulting (Ended: 11/09/2023) |
Boehringer Ingelheim | Advisor or review panel participant (Ended: 09/08/2022) |
UCB | Advisor or review panel participant (Ended: 10/17/2022) |
Horizon Pharma | Advisor or review panel participant (Ended: 09/08/2022) |
Janssen Pharmaceuticals, Inc. | Consulting (Ended: 12/07/2023) |
RhAPP | Teaching and Speaking |
Michelle Petri | |
Aurinia Pharmaceuticals | Teaching and Speaking (Ended: 12/31/2024) Research |
Exagen Diagnostics | Research |
GlaxoSmithKline | Consulting Research |
Janssen | Research (Ended: 12/31/2024) |
Abbvie Pharmaceuticals | Consulting (Ended: 01/01/2025) |
Alexion Duality Bio Gentibio iConPLC Innovaderm Research |
Consulting (Ended: 12/31/2024) |
Amgen | Consulting (Ended: 07/31/2024) |
Anneion Bio Astrazeneca Pharmaceuticals Autolus Bain Capital Baobab Therapeutics BioCryst Pharmaceuticals, Inc. Boxer Capital Caribou Biosciences Inc CVS/Caremark Escient Pharmaceuticals Exo Therapeutics Novartis Ono Pharma USA Owkin Regeneron Pharmaceuticals Seismic Therapeutic Senti Biosciences Steritas Takeda UCB Variant Bio, Inc. Vertex Pharmaceuticals Zydus Pharmaceuticals (USA) Inc. |
Consulting |
Arthros-FocusMedEd | Teaching and Speaking (Ended: 12/31/2023) |
Atara Biotherapeutics | Consulting (Ended: 10/30/2024) |
Avoro Ventures | Consulting (Ended: 04/11/2024) |
Bavarian Nordic EMD Serono, Inc. |
Advisor or review panel participant |
Biogen Idec | Advisor or review panel participant (Ended: 12/31/2024) |
Cabaletta Bio Proviant Sinomab Biosciences |
Consulting (Ended: 01/31/2024) |
CTI Clinical Trial & Consulting Services | Advisor or review panel participant (Ended: 10/30/2024) |
Ermium | Consulting (Ended: 08/31/2024) |
iCell Gene Therapeutics Tenet Medicines Inc |
Consulting (Ended: 11/30/2024) |
IQVIA | Advisor or review panel participant (Ended: 12/31/2023) |
Kira Pharmaceuticals | Consulting (Ended: 03/31/2023) |
Nexstone Immunology | Consulting (Ended: 03/31/2024) |
Nimbus Lakshmi | Consulting (Ended: 07/31/2023) |
PPD Development | Advisor or review panel participant (Ended: 02/28/2024) |
Precision Biosciences | Consulting (Ended: 06/30/2024) |
TG Therapeutics | Consulting (Ended: 05/31/2024) |
Worldwide Clinical Trials | Advisor or review panel participant (Ended: 10/30/2024) |
Michael Putman, MD | |
Abbvie Pharmaceuticals | Research (Ended: 12/01/2024) |
Amgen | Other activities from which remuneration is received or expected (Ended: 12/01/2024) Research (Ended: 12/01/2024) |
Astra Zeneca | Other activities from which remuneration is received or expected (Ended: 12/01/2024) Research |
GSK | Advisor or review panel participant (Ended: 12/01/2024) |
Novartis | Other activities from which remuneration is received or expected (Ended: 12/01/2024) Research (Ended: 12/01/2024) |
Christopher Ritchlin, MD | |
BMS Novartis Pharmaceuticals Janssen |
Consulting Research |
Amgen | Consulting (Ended: 01/01/2024) |
UCB | Consulting Other activities from which remuneration is received or expected |
Abbvie Pharmaceuticals | Consulting Advisor or review panel participant |
MoonLake Immunotherapeutics | Consulting |
All other individuals have indicated no relationship which, in the context of their involvement, could be perceived as a potential conflict of interest.
Acknowledgment
The Cleveland Clinic Center for Continuing Education acknowledges educational grants for partial support of this activity from:
Genentech
Janssen Scientific Affairs, LLC
UCB, Inc.
This CME activity was produced by the Cleveland Clinic Foundation Center for Continuing Education, Cleveland Clinic’s Department of Rheumatic & Immunologic Diseases, and Cleveland Clinic’s RJ Fasenmyer Center for Clinical Immunology.